Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 2025 BIO CEO & Investor Conference. The event will be held on February 10-11, 2025, in New York, NY.
The company's management team, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will engage in one-on-one meetings during the conference. This participation demonstrates Lifecore's commitment to investor relations and market engagement.
Lifecore Biomedical (NASDAQ: LFCR), un'organizzazione completamente integrata per lo sviluppo e la produzione su contratto (CDMO), ha annunciato la sua partecipazione alla 2025 BIO CEO & Investor Conference. L'evento si terrà il 10-11 febbraio 2025, a New York, NY.
Il team di gestione dell'azienda, incluso Paul Josephs, amministratore delegato, e Ryan Lake, direttore finanziario, parteciperà a incontri individuali durante la conferenza. Questa partecipazione dimostra l'impegno di Lifecore nelle relazioni con gli investitori e nel coinvolgimento nel mercato.
Lifecore Biomedical (NASDAQ: LFCR), una organización de desarrollo y fabricación por contrato completamente integrada (CDMO), ha anunciado su participación en la 2025 BIO CEO & Investor Conference. El evento se llevará a cabo el 10-11 de febrero de 2025, en Nueva York, NY.
El equipo directivo de la empresa, que incluye a Paul Josephs, director ejecutivo, y Ryan Lake, director financiero, participará en reuniones individuales durante la conferencia. Esta participación demuestra el compromiso de Lifecore con las relaciones con los inversores y el compromiso con el mercado.
Lifecore Biomedical (NASDAQ: LFCR), 완전 통합 계약 개발 및 제조 조직(CDMO),이 2025 BIO CEO & Investor Conference에 참여할 것이라고 발표했습니다. 이 행사는 2025년 2월 10-11일, 뉴욕에서 개최됩니다.
회사의 경영진, Paul Josephs CEO 및 Ryan Lake CFO가 회의 중 일대일 미팅에 참석할 예정입니다. 이번 참석은 Lifecore의 투자자 관계 및 시장 참여에 대한 헌신을 보여줍니다.
Lifecore Biomedical (NASDAQ: LFCR), une organisation de développement et de fabrication sous contrat entièrement intégrée (CDMO), a annoncé sa participation à la 2025 BIO CEO & Investor Conference. L'événement se déroulera les 10-11 février 2025, à New York, NY.
L'équipe de direction de l'entreprise, y compris Paul Josephs, directeur général, et Ryan Lake, directeur financier, s'engagera dans des réunions individuelles durant la conférence. Cette participation démontre l'engagement de Lifecore envers les relations avec les investisseurs et l'engagement sur le marché.
Lifecore Biomedical (NASDAQ: LFCR), ein voll integriertes Auftragsentwicklungs- und Produktionsunternehmen (CDMO), hat seine Teilnahme an der 2025 BIO CEO & Investor Conference bekannt gegeben. Die Veranstaltung findet am 10.-11. Februar 2025 in New York, NY, statt.
Das Management-Team des Unternehmens, darunter Paul Josephs, CEO, und Ryan Lake, CFO, wird während der Konferenz an Einzelgesprächen teilnehmen. Diese Teilnahme zeigt Lifecores Engagement für Investor Relations und Marktbeteiligung.
- None.
- None.
CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY.
Details regarding Lifecore’s participation are as follows:
- 2025 BIO CEO & Investor Conference
Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings
Conference Dates: February 10-11, 2025
Location: New York, NY
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
FAQ
When is Lifecore Biomedical (LFCR) participating in the 2025 BIO CEO & Investor Conference?
Who will represent Lifecore Biomedical (LFCR) at the 2025 BIO CEO & Investor Conference?
What type of meetings will Lifecore Biomedical (LFCR) conduct at the 2025 BIO CEO Conference?
Where will the 2025 BIO CEO & Investor Conference featuring Lifecore Biomedical (LFCR) take place?
